A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite …
YF Zhang, XL Wang, CH Xu, N Liu, L Zhang… - Frontiers in Cell and …, 2022 - frontiersin.org
The ETO-family transcriptional corepressors, including ETO, ETO2, and MTGR1, are all
involved in leukemia-causing chromosomal translocations. In every case, an ETO-family …
involved in leukemia-causing chromosomal translocations. In every case, an ETO-family …
Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells
H Shima, E Takamatsu-Ichihara… - Blood, The Journal …, 2018 - ashpublications.org
Eradication of chemotherapy-resistant leukemia stem cells is expected to improve treatment
outcomes in patients with acute myelogenous leukemia (AML). In a mouse model of AML …
outcomes in patients with acute myelogenous leukemia (AML). In a mouse model of AML …
From determinants of Runx1/Eto tetramerization to small-molecule protein–protein interaction inhibitors targeting acute myeloid leukemia
A Metz, J Schanda, M Grez, C Wichmann… - Journal of chemical …, 2013 - ACS Publications
We identified the first small-molecule protein–protein interaction inhibitors of RUNX1/ETO
tetramerization applying structure-based virtual screening guided by predicted hot spots and …
tetramerization applying structure-based virtual screening guided by predicted hot spots and …
Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity
S Gajendra, S Anupurba, R Gupta… - International Journal …, 2023 - Wiley Online Library
Introduction Acute myeloid leukemia (AML) with RAM immunophenotype is a distinct
subtype of AML, as described by the Children's Oncology Group (COG), with characteristic …
subtype of AML, as described by the Children's Oncology Group (COG), with characteristic …
Utility of CD36 as a novel addition to the immunophenotypic signature of RAM‐phenotype acute myeloid leukemia and study of its clinicopathological characteristics
D Panda, G Chatterjee, R Sardana… - Cytometry Part B …, 2021 - Wiley Online Library
Abstract Introduction In 2016, Children Oncology Group (COG) described a new high‐risk
subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic‐signature, RAM …
subtype of acute myeloid leukemia (AML) with a distinct immunophenotypic‐signature, RAM …
[HTML][HTML] DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia
Abstract Childhood Acute Myeloid Leukemia (AML) is a clinically and genetically
heterogeneous malignant disease. Despite improvements in outcome over the past …
heterogeneous malignant disease. Despite improvements in outcome over the past …
Interaction with the Bardet-Biedl gene product TRIM32/BBS11 modifies the half-life and localization of Glis2/NPHP7
H Ramachandran, T Schäfer, Y Kim, K Herfurth… - Journal of Biological …, 2014 - ASBMB
Although the two ciliopathies Bardet-Biedl syndrome and nephronophthisis share multiple
clinical manifestations, the molecular basis for this overlap remains largely unknown. Both …
clinical manifestations, the molecular basis for this overlap remains largely unknown. Both …
Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia–related malignancies
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia but is
approximately 500 times more likely to develop in children with Down syndrome (DS) …
approximately 500 times more likely to develop in children with Down syndrome (DS) …
The Pediatric Acute Leukemia Fusion Oncogene ETO2‐GLIS2 Increases Self‐Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells‐Derived …
SN Bertuccio, F Boudia, M Cambot, CK Lopez… - …, 2020 - Wiley Online Library
The ETO2-GLIS2 fusion is associated with young and aggressive pediatric acute
megakaryoblastic leukemia (AMKL) and is thought to arise in utero. To investigate ETO2 …
megakaryoblastic leukemia (AMKL) and is thought to arise in utero. To investigate ETO2 …
[HTML][HTML] Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
S Okabe, T Tauchi, Y Tanaka, K Ohyashiki - Oncotarget, 2018 - ncbi.nlm.nih.gov
Abelson murine leukemia viral oncogene homolog (ABL) tyrosine kinase inhibitors (TKIs)
have been shown to be effective for treatment of chronic myeloid leukemia (CML) and …
have been shown to be effective for treatment of chronic myeloid leukemia (CML) and …